Rhea Sancassani, MD
Cardiovascular Disease · Miami, FLNPI 1003017112
Payments from drug & device makers
Across 123 payments — averaging $121.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$13K
- Novartis$412
- AstraZeneca$326
- E.r. Squibb & Sons, L.L.C.$198
- Johnson & Johnson$194
- Amgen$123
- plus $460 from 16 others
What the payments were for
- Speaking & faculty fees$12,69085%
- Food & beverage$2,20115%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $13,195 |
| Novartis | 22 | $412 |
| AstraZeneca | 19 | $326 |
| E.r. Squibb & Sons, L.L.C. | 10 | $198 |
| Johnson & Johnson | 13 | $194 |
| Amgen | 6 | $123 |
| Lexicon Pharmaceuticals, Inc. | 2 | $56 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $46 |
| Kestra Medical Technology Services, Inc. | 1 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| Humacyte Global, Inc. | 1 | $30 |
| Boston Scientific | 1 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Medtronic | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Canon Medical Systems USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$12,690
How this compares
$14,908 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 36 | $45,519 |
| FarxigaDapagliflozin Propanediol | 30 | $33,249 |
| EliquisApixaban | 20 | $28,130 |
| VascepaIcosapent Ethyl | 11 | $9,716 |
| NexletolBempedoic Acid | 19 | $8,409 |
| Ranolazine ErRanolazine | 17 | $4,305 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $1,708 |
| Isosorbide Dinitrate | 27 | $1,073 |
| Rosuvastatin Calcium | 65 | $896 |
| Ezetimibe | 21 | $657 |
| Nitroglycerin | 18 | $577 |
| Metoprolol Succinate | 33 | $451 |
| Losartan Potassium | 35 | $430 |
| Carvedilol | 61 | $408 |
| Atorvastatin Calcium | 41 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $412 | $45,51936 claims |
| AstraZenecaFarxiga | $326 | $33,24930 claims |
| PfizerEliquis | $13,195 | $28,13020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Miami
- Jonathan FialkowMiami$2.6M
- Melvin Martinez-CastrillonMiami$1.6M
- Theodore FeldmanMiami$637K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.